Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, Artificial Partner on COVID-19 Testing Platform Automation

NEW YORK – Thermo Fisher Scientific and automation software developer Artificial said on Tuesday that they are collaborating to develop an integrated and comprehensive software automation platform for Thermo Fisher's COVID-19 testing platform, enabling higher throughput and support of global healthcare initiatives.

Under the collaboration, Artificial will provide access to its aLab Suite software, which integrates with the Thermo Scientific Momentum Workflow software and robotics hardware. Specifically, the aLab Suite software enables dynamic scheduling of protocol runs with batch optimization, coordinates manual system setup steps associated with process execution of Momentum, and guides lab technicians on loading system consumables.

"This collaboration enables biopharma and contract services companies to both simplify their lab technicians' interactions with automated systems and more efficiently coordinate the use of their multiple Momentum automated systems, increasing productivity and minimizing user intervention to meet industry needs," said Hansjoerg Haas, Thermo Fisher's senior director and general manager of laboratory automation, in a statement.

Financial and other terms of the collaboration were not disclosed. Thermo Fisher said it will provide feedback to Artificial on aLab Suite functionalities and capabilities to inform future product development.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.